Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AEMD logo AEMD
Upturn stock ratingUpturn stock rating
AEMD logo

Aethlon Medical Inc (AEMD)

Upturn stock ratingUpturn stock rating
$1.2
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: AEMD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4.5

1 Year Target Price $4.5

Analysts Price Target For last 52 week
$4.5Target price
Low$1.1
Current$1.2
high$8.44

Analysis of Past Performance

Type Stock
Historic Profit -65.14%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.51M USD
Price to earnings Ratio -
1Y Target Price 4.5
Price to earnings Ratio -
1Y Target Price 4.5
Volume (30-day avg) 1
Beta 1.88
52 Weeks Range 1.10 - 8.44
Updated Date 06/30/2025
52 Weeks Range 1.10 - 8.44
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.58

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -74.82%
Return on Equity (TTM) -245.88%

Valuation

Trailing PE -
Forward PE 0.21
Enterprise Value -2338110
Price to Sales(TTM) 2.37
Enterprise Value -2338110
Price to Sales(TTM) 2.37
Enterprise Value to Revenue 1.07
Enterprise Value to EBITDA 0.24
Shares Outstanding 2010720
Shares Floating 1735388
Shares Outstanding 2010720
Shares Floating 1735388
Percent Insiders 0.94
Percent Institutions 21.15

Analyst Ratings

Rating 1
Target Price 4.5
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Aethlon Medical Inc

stock logo

Company Overview

overview logo History and Background

Aethlon Medical, Inc. was founded in 1991. It is a medical technology company focused on developing therapeutic devices to address unmet needs in global health and biodefense. The company has primarily focused on its Hemopurifieru00ae technology.

business area logo Core Business Areas

  • Therapeutic Blood Filtration: Aethlon Medical's core business revolves around developing and commercializing the Hemopurifieru00ae, a device designed to remove harmful substances from the bloodstream.

leadership logo Leadership and Structure

Aethlon Medical's leadership consists of a board of directors and an executive team. The specific structure and individuals change over time; refer to the company's website or SEC filings for the most current information.

Top Products and Market Share

overview logo Key Offerings

  • Hemopurifieru00ae: The Hemopurifieru00ae is a blood filtration device designed to remove viruses and exosomes from the circulation. It has been investigated in clinical studies for various infectious diseases and cancer. Market share data and revenue figures are not publicly available. Competitors include companies developing blood purification technologies and therapies for the targeted diseases, though the Hemopurifier's specific mechanism is somewhat unique.

Market Dynamics

industry overview logo Industry Overview

The therapeutic blood filtration industry is characterized by innovation in materials science, engineering, and medicine. It caters to a wide range of conditions, from infectious diseases to cancer. The industry is subject to strict regulatory oversight and requires extensive clinical trials for product approval.

Positioning

Aethlon Medical occupies a niche position within the therapeutic blood filtration industry, focusing on broad-spectrum removal of pathogens and exosomes. Its competitive advantage lies in its unique Hemopurifieru00ae technology.

Total Addressable Market (TAM)

The TAM for blood purification technologies is estimated to be in the billions of dollars. Aethlon's positioning allows it to target specific segments within this large market, such as viral diseases and oncology.

Upturn SWOT Analysis

Strengths

  • Novel Hemopurifieru00ae technology
  • Potential for broad-spectrum pathogen removal
  • Investigational device exemption (IDE) approval for certain indications
  • Experienced management team

Weaknesses

  • Reliance on a single product
  • Limited commercialization success to date
  • Significant capital requirements
  • Dependence on regulatory approvals
  • Lack of consistent revenue streams

Opportunities

  • Expansion into new therapeutic areas
  • Partnerships with pharmaceutical companies
  • Government funding for biodefense applications
  • Addressing unmet needs in emerging markets

Threats

  • Competition from established medical device companies
  • Regulatory hurdles and delays
  • Clinical trial failures
  • Difficulty securing funding
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • Baxter International Inc (BAX)
  • Fresenius Medical Care AG & Co. KGaA (FMS)
  • Asahi Kasei Corporation (3407.T)

Competitive Landscape

Aethlon Medical faces competition from larger, more established medical device companies with greater resources. Its advantage lies in its novel technology, but it needs to demonstrate clinical efficacy and secure regulatory approvals to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: Aethlon Medical's growth has been primarily driven by research and development activities rather than revenue generation.

Future Projections: Future growth depends on the successful commercialization of the Hemopurifieru00ae and the development of new applications. Analyst estimates are subject to change.

Recent Initiatives: Recent initiatives may include clinical trials, regulatory submissions, and partnerships. Refer to the company's press releases and investor presentations for updates.

Summary

Aethlon Medical is a developmental-stage company with a novel blood filtration technology. Its success hinges on the successful commercialization of the Hemopurifieru00ae, which requires positive clinical trial results and regulatory approvals. The company faces significant financial and competitive challenges. However, partnerships and government funding could boost their market position.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (10-K, 10-Q)
  • Company Website
  • Financial News Outlets

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aethlon Medical Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2001-01-02
CEO, CFO, Secretary & Director Mr. James B. Frakes M.B.A.
Sector Healthcare
Industry Medical Devices
Full time employees -
Full time employees -

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening viral infectious, diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.